التفاصيل البيبلوغرافية
| العنوان: |
DataSheet_1_Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.docx |
| المؤلفون: |
Antti Nätynki, Päivi Leisti, Jussi Tuusa, Outi Varpuluoma, Laura Huilaja, Kentaro Izumi, Sanna-Kaisa Herukka, Olavi Ukkola, Juhani Junttila, Nina Kokkonen, Kaisa Tasanen |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, bullous pemphigoid, BP180, gliptins, DPP4, SDF-1 (CXCL12) |
| الوصف: |
The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP autoantigen BP180 in serum samples from patients with type 2 diabetes (T2D) with preceding gliptin medication (n = 136) or without (n = 136). Sitagliptin was the most frequently prescribed gliptin (125/136 patients). Using an ELISA assay, we showed that IgG autoantibodies against the immunodominant NC16A domain of BP180 were found in 5.9% of gliptin treated and in 6.6% of non-gliptin treated T2D patients. We found that 28% of gliptin treated patients had IgG autoantibodies recognizing the native full-length BP180 in ELISA, but among non-gliptin treated the seropositivity was even higher, at 32%. Further ELISA analysis of additional serum samples (n = 57) found no major changes in the seropositivity against BP180 during a follow-up period of about nine years. In immunoblotting, full-length BP180 was recognized by 71% of gliptin treated and 89% of non-gliptin treated T2D patients, but only by 46% of the age-and sex-matched controls. The chemokine stromal derived factor-1(SDF-1/CXCL12) is one of the major substrates of DPP4. Immunostainings showed that the expression of SDF-1 was markedly increased in the skin of BP patients, but not affected by prior gliptin treatment. We found that the use of gliptins decreased the serum level of SDF-1α in both BP and T2D patients. Our results indicate that the autoantibodies against the linear full-length BP180 are common in patients with T2D, but seropositivity is unaffected by the use of sitagliptin. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/dataset/DataSheet_1_Use_of_gliptins_reduces_levels_of_SDF-1_CXCL12_in_bullous_pemphigoid_and_type_2_diabetes_but_does_not_increase_autoantibodies_against_BP180_in_diabetic_patients_docx/20365980Test |
| DOI: |
10.3389/fimmu.2022.942131.s001 |
| الإتاحة: |
https://doi.org/10.3389/fimmu.2022.942131.s001Test
https://figshare.com/articles/dataset/DataSheet_1_Use_of_gliptins_reduces_levels_of_SDF-1_CXCL12_in_bullous_pemphigoid_and_type_2_diabetes_but_does_not_increase_autoantibodies_against_BP180_in_diabetic_patients_docx/20365980Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.8137DCCC |
| قاعدة البيانات: |
BASE |
